Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
32 authors.
Daniel J ZhengDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0003-2217-088X
Gary HettingerDepartment of Population Health, New York University Grossman School of Medicine, New York, NY, United States.ORCID 0000-0001-5980-2946
Catherine AftandilianDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, Stanford University, Palo Alto, CA, United States.ORCID 0000-0001-9775-2839
Kira BonaDepartment of Pediatric Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, United States.ORCID 0000-0001-5602-7059
Emi H CaywoodDepartment of Pediatrics, Thomas Jefferson University, Philadelphia, PA, United States.ORCID 0000-0002-2873-6058
Anderson B CollierPediatric Hematology/Oncology, Nemours Children's Health, Jacksonville, FL, United States.ORCID 0000-0001-7183-7826
Caitlin W ElgartenDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-2474-3031
Cody GathersDivision of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0001-6294-6289
Taumoha GhoshDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, Primary Children's Hospital/University of Utah, Salt Lake City, UT, United States.ORCID 0000-0003-3420-3167
M Monica GramatgesBaylor College of Medicine, Texas Children's Hospital, Houston, TX, United States.ORCID 0000-0002-0947-104X
Meret HenryDepartment of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, Children's Hospital of Michigan, Detroit, MI, United States.
Yuan-Shung V HuangDepartment of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-1942-6197
Yimei LiDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0001-9067-6992
Craig LottermanPediatric Hematology and Oncology, Ochsner Medical Center for Children, New Orleans, LA, United States.
Kelly MaloneyChildren's Hospital Colorado and the Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States.
Amir MianDivision of Pediatric Hematology/Oncology, Dell Children's Hospital, University of Texas-Austin, Austin, TX, United States.ORCID 0009-0005-1178-727X
Tamara P MillerAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States.ORCID 0000-0003-4250-5376
Arunkumar ModiDivision of Pediatric Hematology Oncology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR, United States.ORCID 0000-0002-9323-8979
Rajen ModySection of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States.ORCID 0000-0001-5574-1779
Elaine MorganPediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States.
Regina MyersDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-2542-2061
Haley NewmanDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-3022-8052
Jose OrtizDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0009-0009-1432-5301
Alix E SeifDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-1799-2582
Caroline SmithDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, United States.ORCID 0000-0002-9154-6855
Jamie StokkePediatric Hematology-Oncology, Children's Hospital of Los Angeles, CA, United States.
Xin WangDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0001-9827-3098
Naomi WinickDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, United States.ORCID 0000-0002-6636-3870
Jennifer J WilkesDepartment of Pediatrics, Division of Hematology/Oncology, University of Washington School of Medicine, Seattle Children's Hospital, Seattle, WA, United States.ORCID 0000-0002-3806-6019
Victor WongDivision of Pediatric Hematology Oncology, Rady Children's Hospital San Diego, San Diego, CA, United States.
Richard AplencDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Kelly D GetzDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0003-2020-5153
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Physician Scientist Training in Clinical OncologyK12CA076931 · NCI · UNIVERSITY OF PENNSYLVANIA · PI STEPHEN Patrick HUNGER, LYNN M. SCHUCHTER · 1997 to 2026
$16.5M
Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and ImplicationsR01HL164925 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Kelly Diringer Getz · 2022 to 2026
$2.6M
Predicting and Monitoring for Cardiac Toxicity in Pediatric AMLR01HL163657 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Richard Aplenc, Kelly Diringer Getz · 2023 to 2026
$2.6M
American Society of Clinical Oncology Conquer CancerNCI NIH HHS K12 CA076931NCI NIH HHS K12CA076931-22NCI NIH HHS P30 CA008748NHLBI NIH HHS R01 HL163657NHLBI NIH HHS R01HL163657NHLBI NIH HHS R01 HL164925NHLBI NIH HHS R01HL164925NIH HHSNovartis Oncology EndowedPCORI Methods ME-2021C3-24942PCORI Methods R01HL163657St Baldrick's ScholarYoung Investigator Award in Health Disparities
6 · The paper itself
Abstract
Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children's Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to the real-world. We addressed this knowledge gap using a nationally representative real-world cohort of 913 pediatric AML patients. Distributions of cytomolecular risk profiles and individual markers were comparable for trial-enrolled and non-enrolled patients, as well as across social drivers of trial enrollment (race/ethnicity, language, insurance, acuity). Compared to patients with only favorable cytomolecular markers (4-year overall survival [OS] = 89.48%; 95% CI = 84.46% to 92.95%), patients with both favorable and unfavorable (hazards ratio [HR] = 2.49, 95% CI = 1.18 to 5.23), neutral (HR = 4.33, 95% CI = 2.75 to 6.82), and only unfavorable (HR = 5.80, 95% CI = 3.70 to 9.11) markers all had increased hazards of death. Cytomolecular risk informed by trial data appears to be generalizable to the real-world setting in pediatric AML.
Indexed as
Biomarkers, TumorLeukemia, Myeloid, AcuteAdolescentAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolClinical Trials, Phase III as TopicCohort StudiesFemaleHumansInfantMalePrognosisRisk AssessmentBiomarkers, Tumor
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. · full record | OpenQuestion